PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031 demark Office; U.S. DEPARTMENT OF COMMERCE

er AF	rw & Reduction Act of 1995	, no pe	rsons are required to resp	oond to a collection of information unle	ss it di	a valid OMB control number.		
Substitu	ute for form 49A/PTO			Complete if Known				
MAY 1	0 2001			Applicati n Number	09/691,343			
NFORM FION DISCLOSURE				Filing Date	Octob	r 18, 2000		
SCT/	ATEMENT BY	ΔΕ	PLICANT	First Named Inventor	Turner			
VE TR	ADEMARK	<i>-</i> \		Group Art Unit	1645	1647		
	(use as many sheets			Examiner Name	To Be Assigned			
Sheet	1	of	3	Attorney Docket Number	LEX-007	0-USA		

				U.S. PATENT DOCUMEN	TS			
Examiner Initials*	Cite	U.S. Patent	Document	Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,		
	No.1	Number Kind Code² (if known)		of Cited Document	of cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
-12.m	AA	4,190,496		Rubenstein et al	02/26/80			
170	AB	4,215,051		Schroeder et al	07/29/80			
	AC	4,376,110		David et al	03/08/83			
	AD	4,683,202		Mullis	07/28/87			
	AE	4,873,191		Wagner et al	10/10/89			
	AF	4,946,778		Ladner et al	08/07/90			
	AG	5,075,217		Weber	12/24/91			
\neg t $^-$	АН	5,364,759		Caskey et al	11/15/94			
	Al	5,625,048		Tsien et al	04/29/97			
A wa	AJ	5,877,397		Lonberg et al	3/2/99			
14(T)	AK	6,075,181		Kucherlapati et al	6/13/00			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite	F	oreign Patent Docu	ment	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant	
	No.1	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)		cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
JAN)	AL	Askew et al, 1989, "Molecular Recognition with Convergent Functional Groups, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components", J. Am. Chem. Soc. 111:1082-1090.				
AM Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.						
	AN	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.				
	AO	Butler, 1981, "The Amplified ELISA: Principles of and Applications for the Comparative Quantitiation of Class and Subclass Antibodies and the Distribution of Antibodies and Antigens in Biochemical Seperates", Methods in Enzymology 73:482-523.				
	AP	Chien et al, 1991, "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest", Proc. Natl. Acad. Sci. USA 88:9578-9582.				
AW	AQ	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.				

Examiner Signature	RM	TOBLERY	Date Considered 11/2/02	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Paper NO:5

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031 Trademark Office; U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box
Pa
'Under the Paperwork Reduction Act of 1995, no persons are resolved to respond to a collection of information unless in

Page 1 d Trademark Office; U.S. DEPA ess it says a valid OMB control number.

Substitute for form 1449B/PTO	MAY 1 0 2001	
INFORMATION STATEMENT B	SISCLOSU	ŘΕ
STATEMENT B	A XIND FIGH	NT

(use as many sheets as necessary)

Complete if Known

Application Number 09/691,343

Filing Dat October 18, 2000

First Named Inventor Turner

Group Art Unit 1649 1647

Examiner Name To Be Assigned

Attorney Docket Number LEX-0070-USA

		·	1		Examiner Name	TO DE Assigned		
Sheet		2	of 3 Attorney Docket Number LEX-0070-USA			LEX-0070-USA		
					MALI BATHLIE I ITTE ATIVE	DOCUMENTO		
			0	THER PRIOR ART	NON PATENT LITERATURE	DOCUMENTS	_	
Examiner Initials*	Cite No. ¹			agazine, journal, ser		article (when appropriate), title of the date, page(s), volume-issue number(s), published.	T ²	
ff	AR	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6625-6641.						
	AS	Gordon, 1989,	"Trans	genic Animals", Inter	national Review of Cytology, 11	I5:171 -22 9.		
	AT	Greenspan et a	al, 1990	3, "Idiotypes: structur	e and immunogenicity", FASEB	3 Journal 7:437-444.		
	AU	Gu et al, 1994, Science 265:10			erase β Gene Segment in T Cell	ls Using Cell Type-Specific Gene Targeting",		
	AV	Houghten et al, discovery", Nat			e of synthetic peptide combinato	orial libraries for basic research and drug		
	AW	Huse et al, 198 Science 246:12			Combinatorial Library of the Imm	nunoglobulin Repertoire in Phage Lambda",		
	AX	Huston et al, 19 chain Fv analog	988, "P gue pro	rotein engineering o oduced in Escherichi	f antibody binding sites: Recove a coli", Proc. Natl. Acad. Sci. Ut	ery of specific activity in an anti-digoxin single- SA 85:5879-5883.		
AY Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.								
AZ Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", Nucle Acids Research 15(15):6131-6149.								
	ВА	Inouye & Inouye 3110.	e, 198	5, "Up-promoter muta	ations in the lpp gene of Escher	ichia coli", Nucleic Acids Research 13(9):3101-		
	ВВ			, "Rapid and efficient USA 88:8972-8976		agged protein expressed by recombinant		
	ВС	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.						
	BD	Lakso et al, 1992, "Targeted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. Sci. USA 89:6232-6236.						
	BE	Lam et al, 1991	m et al, 1991, "A new type of synthetic peptide library for identifying ligand-binding activity", Nature 354:82-86.					
	BF	Exercised Floring Flor						
	BG	Lewis et al, 198 generation", Pro	39, "Au oc. R.	tomated site-directed Soc. Lond. B 236:14	d drug design: the formation of r 1-162.	molecular templates in primary structure		
	ВН	Lo, 1983, "Tran Cell. Biology 3(Microinjection of DNA: Multiple	e Integrations without Tandem Insertions", Mol.	&	
	ВІ	Logan et al, 198 Acad. Sci. USA			ader sequence enhances transl	lation of mRNAs late after infection", Proc. Natl.		
	BJ	Lowy et al, 198	0, "Iso	lation of Transformin	g DNA: Cloning the Hamster ap	ort Gene", Cell 22:817-823.		
	ВК	McKinlay et al,	1989,	"Rational Design of A	Antiviral Agents", Annu. Rev. Ph	narmacol. Toxicol. 29:111-122.		
	BL			'Chimeric human ant Acad. Sci. USA 81:6		n-binding domains with human constant region		
	ВМ				nal cells that express the Escher cad. Sci. USA 78(4):2072-2076.	richia coli gene coding for xanthine-guanine		
/ /	BN	Neuberger et a	I, 1984	, "Recombinant antib	oodies possessing novel effecto	or functions", Nature 312:604-608.		
RW	ВО	Nisonoff, 1991,	"Idioty	pes: Concepts and	Applications", J. of Immunology	147:2429-2438.		
						 		

RM Delly

11/102

papel NO:5

ays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons an equired to respond to a collection of information unless.

Substitute for form 1449B/PTO

INFORMATION DISCLOSERE

Application Number

One of the Paperwork Reduction Act of 1995, no persons an equired to respond to a collection of information unless.

Com
Application Number

One of the Paperwork Reduction Act of 1995, no persons an equired to respond to a collection of information unless.

(use as many sheets as necessary)

of

Please type a plus sign (+) inside this box

Sheet

RE Fil

3

Complete if Known						
Applicati n Number	09/691,343					
Filing Date	Oct b r 18, 2000					
First Named Invent r	Turner					
Group Art Unit	1645 1647					
Examiner Name	To Be Assigned					
Attorney Docket Number	LEX-0070-USA					

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Cité No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
Rh	BP	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.					
	ВС	Ripka, 1988, "Computers picture the perfect drug", New Scientist 16:54-57.					
	BR	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.					
	BS	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.					
	ВТ	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.					
	BU	Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.					
	BV	Songyang et al, 1993, "SH2 Domains Recognize Specific Phosphopeptide Sequences", Cell 72:767-778.					
	BW	Stein et al, 1988, "Physiochemical properties of phosphorothicate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.					
	ВХ	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.					
	ВҮ	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.					
	BZ	Thompson et al, 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells", Cell 56:313-321.					
	CA	Van Der Putten et al, 1985, "Efficient insertion of genes into the mouse germ line via retroviral vectors", Proc. Natl. Acad. Sci. USA 82:6148-6152.					
	CB	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 264(10):5503-5509.					
	CC	Voller et al, 1978, "Enzyme immunoassays with special reference to ELISA techniques", J. Clinical Pathology 31:507-520.					
	CE	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature 341:544-546.					
	CE	Wigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. USA 77(6):3567-3570.					
RN	1/) CF	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cell", Cell 11:223-232.					

						_
Examiner Signature	RM MO	Man	Date Considered	11/1	102	
					,	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.